Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

NCT03449108 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03449108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03449108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 27, 2018
Completion date
April 30, 2027
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone sarcoma, dedifferentiated chondrosarcoma, giant cell tumor of bone, malignancy in giant cell tumor of bone, malignant solid neoplasm, ovarian carcinosarcoma, platinum-resistant ovarian carcinoma, poorly differentiated thyroid gland carcinoma, recurrent osteosarcoma, recurrent ovarian carcinoma, refractory osteosarcoma, soft tissue sarcoma, thyroid gland anaplastic carcinoma, thyroid gland squamous cell carcinoma, triple negative breast cancer, undifferentiated high grade pleomorphic sarcoma of bone